Stock Price & Analysis

Buy BSX stock as analysts predict significant upside potential and the company continues to show strong financial performance. The stock is well-positioned for long-term growth with a positive outlook from both fundamental and technical perspectives.

Boston Scientific (BSX) is expected to reach a price of $118 by 2025, driven by strong earnings growth and successful integration of Silk Road and Axonics. Analysts have raised price targets, with Barclays and Stifel setting targets of $118 and $120, respectively. The stock's current momentum and positive analyst sentiment support this bullish outlook.

The S1 support level for BSX Stock is $98.69 ,The R1 resistant level for BSX Stock is $103.66.

As of the end of day on 2025-04-02, the price of BSX Stock was $101.23.

The target price for BSX Stock according to analyst rating is 118.95, with the highest price target at 135.00 and the lowest at 100.00. Analysts have a Strong Buy rating on BSX Stock overall.

The market cap of BSX is $149.7B.

Analysis and Insights

Valuation Metrics:

Boston Scientific (BSX) is trading at $101.19 with a forward P/E of 25.23, which is slightly above its peer average. The EV/EBITDA ratio of 18.23 suggests a premium valuation, but this is justified by its strong revenue growth of 22.44% and net margin of 12.39%.

Analyst Sentiment:

Analysts have raised their price targets, with an average target of $114.88, indicating 13.5% upside potential. Most maintain a "Buy" or "Strong Buy" rating, reflecting confidence in BSX's growth prospects.

Technical Analysis:

The stock shows a neutral RSI of 51.04, with a MACD slightly below zero, indicating a stable trend. It's trading above its 20, 50, and 200-day moving averages, signaling bullish momentum.

Recent Developments:

The acquisition of SoniVie expands BSX's hypertension treatment portfolio, aligning with its growth strategy and enhancing its competitive position.

Conclusion:

BSX is fairly valued with growth potential, supported by strong financials and positive analyst sentiment. It is not overvalued at its current price.

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company’s segments include MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. The Cardiovascular segment includes Cardiology and Peripheral Interventions. The Company's Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions.

Price Prediction for BSX Stock by 2030

Based on current trends and analyst expectations, Boston Scientific (BSX) is projected to reach a stock price of $150 by 2030, driven by strong growth in its medical device portfolio and strategic acquisitions.

• Reasoning:
  • BSX has shown consistent revenue growth, with a 22.44% increase in the last quarter of 2024, and a net margin of 12.39%, outperforming industry peers.
  • Analysts have raised their price targets, with an average 12-month target of $114.88 and a high estimate of $130, reflecting confidence in the company's future performance.
  • Strategic acquisitions, such as Bolt Medical, and strong earnings growth position BSX for long-term success in the medical device sector.

BSX has a total of 48000 employees.